Expanding possibilities for diverse preclinical models

AMSBIO has broadened its array of products and services dedicated to supporting scientists in effectively diversifying their preclinical models, addressing the gender discrepancy gap prevalent in various research areas.

Historically, clinical trials predominantly involved men of European descent until 1993, resulting in limited data on treatment safety and efficacy for women and diverse populations. While attitudes in clinical trials are evolving, inclusivity in preclinical research often remains overlooked, creating crucial knowledge gaps regarding the impact of drugs and treatments on different populations even before advancing to human trials.

In a recent blog commemorating International Women's Day, AMSBIO discusses the potential use of an envisioned intestinal organoid biobank to address accessibility challenges. The blog also highlights the gender reporting issues in COVID-19 vaccine development, where women experienced a disproportionate number of side effects, underreported due to aggregated data.

As a global provider of human and animal biospecimens, AMSBIO contributes to increasing diversity in research. The company's extensive biorepository houses various tissues from reliable sources, encompassing a comprehensive selection of healthy tissues and a variety of disease states from diverse genders and ethnicities. For specific research requirements, AMSBIO offers a custom tissue procurement service to provide samples tailored to the complexities of donor demographics.

Additionally, through a powerful synergy of novel organoids and proprietary lab-on-a-chip technology from partner ScreenIn3D (S3D), AMSBIO is uniquely positioned to assist preclinical researchers in cost-effectively developing high-throughput, data-rich assays.

Alex Sim, CEO of AMSBIO, emphasised: "A significant impetus for future clinical trials emerged from the US Federal Drug Administration in 2023. The new FDA 2.0 legislation introduces additional stratification in research by mandating more demographic requirements, including gender and race, for clinical trials and research programs. Both AMSBIO and ScreenIn3D can facilitate your research to translate this for societal benefit and the positioning of combination therapies."

Read the informative new blog ‘Diversifying Preclinical Research’.

More information online